Brought to you by 
Collateral Therapeutics, NYU ally on FGF gene therapy tech
04 Aug 2000
Executive Summary
Collateral Therapeutics exclusively licensed from New York University the rights to commercialize and develop certain patents and patent applications covering Fibroblast Growth Factor 4 (FGF-4) for gene therapy products.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Collateral Therapeutics, NYU ally on FGF gene therapy tech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice